This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 10/30/2026
| | Dilution volume | Initial rate (first hour) | Rate incrementa | Maximum rate |
|---|---|---|---|---|
| Week 1 infusion | ||||
| Option 1 (Single-dose infusion) | ||||
| Week 1 Day 1 (16 mg/kg) | 1000 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| Option 2 (Split-dose infusion) | ||||
| Week 1 Day 1 (8 mg/kg) | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| Week 1 Day 2 (8 mg/kg) | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| Week 2 (16 mg/kg) infusionb | 500 mL | 50 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| Subsequent (Week 3 onwards, 16 mg/kg) infusionsc | 500 mL | 100 mL/hour | 50 mL/hour every hour | 200 mL/hour |
| aConsider incremental escalation of the infusion rate only in the absence of infusion reactions. bUse a dilution volume of 500 mL for the 16 mg/kg dose only if there were no infusion reactions the previous week. Otherwise, use a dilution volume of 1000 mL. cUse a modified initial rate (100 mL/hour) for subsequent infusions (i.e. Week 3 onwards) only if there were no infusion reactions during the previous infusion. Otherwise, continue to use instructions indicated in the table for the Week 2 infusion rate. | ||||
A literature search of MEDLINE®
| 1 | Data on File. Daratumumab Intravenous Formulation CCDS. Janssen Research & Development, LLC. EDMS-ERI-78724630; 2026. |
Would you like to clear and leave your conversation? Message history will be lost.